Mississippi is currently home to 395 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Jackson, Tupelo, Hattiesburg and Flowood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934
Recruiting
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/03/2024
Locations: Research Site, Oxford, Mississippi
Conditions: ER-Positive HER2-Negative Breast Cancer
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
06/03/2024
Locations: Not set, Hattiesburg, Mississippi
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
Female
Ages:
Between 18 years and 60 years
Trial Updated:
05/31/2024
Locations: Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi
Conditions: Breast Cancer
Register for Updates
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05705401
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
All
Ages:
40 years and above
Trial Updated:
05/31/2024
Locations: Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi
Conditions: HER2-positive Breast Cancer
Register for Updates
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: aTyr Investigative Site, Jackson, Mississippi
Conditions: Pulmonary Sarcoidosis
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
All
Ages:
Between 29 days and 21 years
Trial Updated:
05/31/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Acute Myeloid Leukemia
Register for Updates
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
05/31/2024
Locations: Gulfport Memorial Hospital, Gulfport, Mississippi
Conditions: Stage I Breast Cancer
Register for Updates
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638
Recruiting
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)
NCT04296903
Recruiting
The ApiFix MID-C System is a unidirectional expandable rod, designed to be connected unilaterally to the spine via 2 anchor points on the concave side of a scoliotic deformity above and below the apex of the major curvature to treat adolescent idiopathic scoliosis. The MID-C System is designed to act as an internal brace. Patients implanted with the device in the US within 2 years of FDA's approval of H17001 should be enrolled in the study. A minimum number of 200 patients will be enrolled in th... Read More
Gender:
All
Ages:
10 years and above
Trial Updated:
05/31/2024
Locations: Univ. of Mississippi Medical Center (UMMC), Jackson, Mississippi
Conditions: Adolescent Idiopathic Scoliosis
Register for Updates
Abbott Atrial Fibrillation Post Approval Study
NCT05434650
Recruiting
This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) for the treatment of AF.
Gender:
All
Ages:
All
Trial Updated:
05/30/2024
Locations: North Mississippi Medical Center, Tupelo, Mississippi
Conditions: Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Register for Updates
Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial
NCT03283878
Recruiting
The Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty (TKA): Multi-Center Trial is a study that will compare the effectiveness of various perioperative strategies for antibiotic delivery as prophylaxis for periprosthetic joint infections (PJI) and surgical site infection in elective primary TKA. The investigators hypothesize that a single dose of prophylactic antibiotic administered within 60 minutes before the incision is not an effective way to prevent PJI in elect... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University Of Mississippi Medical Center, Jackson, Mississippi
Conditions: Arthropathy of Knee, Antibiotic Prophylaxis
Register for Updates
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173
Recruiting
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2024
Locations: Hattiesburg Clinic - Memory Center, Hattiesburg, Mississippi
Conditions: Alzheimer Disease
Register for Updates